Search results for "Peni"

showing 10 items of 1692 documents

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.

2021

Introduction Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly. Areas covered Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP (iTTP). Available bibliography about iTTP treatment has been searched in Library's MEDLINE/PubMed database from January 1990 until April 2021. Expert opinion The general…

medicine.medical_specialtyPurpura Thrombocytopenic IdiopathicThrombotic microangiopathyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industrymedicine.medical_treatmentThrombotic thrombocytopenic purpuraADAMTS13 ProteinHematologyMicroangiopathic hemolytic anemiaDiseasemedicine.diseaseADAMTS13Targeted therapyPharmaceutical Preparationshemic and lymphatic diseasesmedicineHumansRituximabCaplacizumabIntensive care medicinebusinessRituximabmedicine.drugExpert review of hematology
researchProduct

PROSPECTIVE, RANDOMIZED, CROSSOVER COMPARISON OF SUBLINGUAL APOMORPHINE (3 mg) WITH ORAL SILDENAFIL (50 mg) FOR MALE ERECTILE DYSFUNCTION

2004

Abstract: Purpose: We established the efficacy and safety of sublingual apomorphine compared with oral sildenafil. in comparable groups of patients with erectile dysfunction (ED). Materials and Methods: This prospective, randomized, crossover study included 77 heterosexual men with ED of various etiologies and severities. A total of 62 men were randomized but only 34 were evaluable for efficacy and tolerability. The study started with a run-in period of 2 to 4 weeks. The first 4 weeks of treatment were followed by a washout period of 4 weeks, after which patients changed to the alternate treatment for an additional 4-week period. The sequence of the 2 treatments was established by a randomi…

medicine.medical_specialtyRandomizationmedicine.drug_mechanism_of_actionSildenafilUrologyUrologyPenis Impotence Apomorphine SildenafilSildenafil 50 MGlaw.inventionSettore MED/24 - Urologiachemistry.chemical_compoundRandomized controlled triallawmedicineProspective cohort studybusiness.industryMale erectile dysfunctionmedicine.diseaseCrossover studyrespiratory tract diseasesApomorphineErectile dysfunctionmedicine.anatomical_structureTolerabilitychemistryAnesthesiacardiovascular systemSexual functionbusinessPhosphodiesterase 5 inhibitorPenismedicine.drug
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Effects of Resistance Training of Peripheral Muscles Versus Respiratory Muscles in Older Adults With Sarcopenia Who are Institutionalized: A Randomiz…

2018

[EN] This study compares the effects of two resistance training programs in peripheral and respiratory musculature on muscle mass and strength and physical performance and identifies the appropriate muscle mass parameter for assessing the intervention effects. Thirty-seven institutionalized older Spanish adults with sarcopenia were analyzed: control group (n = 17), respiratory muscle training group (n = 9), and peripheral muscle training group (n = 11). Measured outcomes were appendicular skeletal muscle mass (ASM/height(2), ASM/weight, and ASM/BMI), isometric knee extension, arm flexion and handgrip strength, maximal inspiratory and expiratory pressures, and gait speed pre- and postinterve…

medicine.medical_specialtySarcopeniaAgingESTADISTICA E INVESTIGACION OPERATIVANursing homesPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionBody Mass IndexExercise training03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumans030212 general & internal medicineRespiratory systemMuscle SkeletalAged030214 geriatricsHand Strengthbusiness.industryMuscle strengthPreventionRehabilitationBody WeightResistance trainingInstitutionalizationResistance Trainingmedicine.diseasemusculoskeletal systemBody HeightRespiratory MusclesPeripheralWalking SpeedSpainSarcopeniaMuscle strengthPhysical therapyGeriatrics and GerontologybusinessNursing homesGerontology
researchProduct

Association between sarcopenia and diabetes: a systematic review and meta-analysis of observational studies

2019

To summarize the prevalence of diabetes in people with sarcopenia (and vice versa) through a meta-analytic approach of available observational studies. In this work, we have presented the findings of the first full methodological systematic review and meta-analysis of observational studies exploring the relationship between diabetes and sarcopenia. Our findings overall emphasize the reciprocal relationship between diabetes and sarcopenia in terms of risk of occurrence, that is sarcopenia increases the risk of diabetes being present and vice versa. This study provides support for further research into the prognosis of people with both diabetes and sarcopenia and the value of interventional s…

medicine.medical_specialtySarcopeniaDiabetePhysical performance03 medical and health sciences0302 clinical medicineInsulin resistancesystematic reviewInternal medicineDiabetes mellitusmedicine030212 general & internal medicine030214 geriatricsbusiness.industryConfoundingDiabetesOdds ratiomusculoskeletal systemmedicine.diseaseConfidence intervalbody regionsMeta-analysisSarcopeniaMeta-analysisObservational studybusinesshuman activities
researchProduct

Muscle Strength and Physical Performance Are Associated with Reaction Time Performance in Older People

2021

Background: Functional mobility and muscle strength are well known risk factors for sarcopenia. Furthermore, possible associations have been suggested between predisposing factors of sarcopenia and reaction time among the elderly. This study aims to analyze possible associations of functional mobility and muscle strength and reaction times in a population of people aged &gt

medicine.medical_specialtySarcopeniaHealth Toxicology and MutagenesisPopulationPhysical fitnessAnciano030209 endocrinology & metabolismPhysical functionelderlyArticlesarcopenia03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationphysical functionReaction TimeMedicineHumans030212 general & internal medicineMuscle StrengtheducationMuscle SkeletalAgededucation.field_of_studyInflamaciónHand Strengthbusiness.industryPublic Health Environmental and Occupational HealthRPhysical Functional Performancemusculoskeletal systemmedicine.diseaseConfidence intervalCross-Sectional StudiesPhysical performanceNutriciónSarcopeniaMuscle strengthphysical fitnessreaction timesMedicinebusinessOlder peopleDesarrollo fisiológicohuman activitiesInternational Journal of Environmental Research and Public Health
researchProduct

Can Vitamin D deficiency influence muscle perfomance in post-menopausal women? A multicenter retrospective study

2018

Background: The presence of the vitamin D receptor (VDR) has been recently demonstrated in human muscle supporting the theory of a role of vitamin D in the proliferation and differentiation of muscle cells. So far only few studies investigated the association between vitamin D and muscle performance in postmenopausal women. Aim: To define the functional impact of vitamin D deficiency. Design: Multicenter retrospective study. Setting: Five Italian outpatient services of Physical and Rehabilitation Medicine (PRM). Population: Postmenopausal women. Methods: We divided the population in two groups based on the threshold of 30 ng/mL as cut-off to define sufficient and insufficient serum levels o…

medicine.medical_specialtySarcopeniaPopulation030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseWalkingGastroenterologyCalcitriol receptorvitamin D deficiency03 medical and health sciencesGrip strength0302 clinical medicineHand strengthInternal medicinemedicineVitamin D and neurologyHumans030212 general & internal medicineMuscle StrengthVitamin DeducationAgedRetrospective Studieseducation.field_of_studyVitamin D post menopausal women Knee isometric extension strenght hand grip strenghtHand Strengthbusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaRehabilitationMiddle Agedmedicine.diseaseVitamin D DeficiencyPostmenopausePhysical FitnessPhysical therapyLean body massFemalevitamin D vitamin D deficiency sarcopenia muscle strengthbusiness
researchProduct

Subarachnoid Hemorrhage Revealing Moyamoya Syndrome in a Patient With May-Hegglin Anomaly.

2017

Etude de cas; Introduction: Moyamoya syndrome is a rare progressive cerebrovascular occlusive disease for which several associated conditions have been described. Case Report: We report the case of a 76-year-old woman with a history of May-Hegglin anomaly who presented with an isolated unusual diffuse headache. Initial laboratory investigations showed only thrombocytopenia (platelet count 95000/mu L). Unenhanced brain computed tomography scan revealed a small subarachnoid hemorrhage in the left frontal lobe. Computed tomography angiography showed occlusion of the terminal portion of the left internal carotid artery (ICA) and narrowing of the terminal portion of the right ICA with abnormal c…

medicine.medical_specialtySubarachnoid hemorrhageMay-Hegglin anomalyHearing Loss SensorineuralOcclusive diseaseLeft frontal lobe030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineAneurysm[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemOcclusionmedicineHumansComputed tomography angiographyAgeddiseasemedicine.diagnostic_testbusiness.industryBrainGeneral MedicineSubarachnoid Hemorrhagemedicine.diseasestrokeThrombocytopeniaStenosismoyamoyaMay–Hegglin anomaly[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]FemaleNeurology (clinical)RadiologyMoyamoya DiseasebusinessTomography X-Ray Computed030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe neurologist
researchProduct

Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange

2012

Systemic lupus erythematosus (SLE) has been described as a cause of thrombotic microangiopathy, especially thrombotic thrombocytopenic purpura (TTP). Haemolytic-uraemic syndrome (HUS) is less frequent in SLE. We report a case of such an association during an episode of severe lupus nephritis in a young woman, who was successfully treated with steroids, cyclophosphamide and especially plasma exchange with plasma replacement. This report highlights the importance of recognising atypical HUS in SLE patients by looking for schistocytes in case of haemolytic anemia with a negative antiglobulin test, in order to begin plasma exchange.

medicine.medical_specialtyThrombotic microangiopathyCyclophosphamidebusiness.industryAnemiaThrombotic thrombocytopenic purpuraLupus nephritismedicine.diseaseGastroenterologySchistocytePharmacotherapyimmune system diseaseshemic and lymphatic diseasesInternal medicineInternal MedicineMedicineskin and connective tissue diseasesbusinessAnti-SSA/Ro autoantibodiesmedicine.drugInternal Medicine Journal
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct